Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease

Hai-Yong Liang; Pei-Pei Zhang; Xi-Le Zhang; Yan-Yan Zheng; Yan-Ran Huang; Guo-Qing Zheng; Yan Lin

doi:doi:10.18632/aging.202619

← Back

Research Paper Volume 13, Issue 5 pp 7549—7569

Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease

Figure 6. Forest plots of the effect of ginsenoside Rg1 for anti-oxidation. Ginsenoside Rg1 (A) improved the activity of SOD; (B) decreased the level of MDA; (C) improved the activity of GSH; (D) improved the activity of GSH-PX; (E) decreased the level of ROS compared with a control group.